MX2010001577A - Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. - Google Patents

Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Info

Publication number
MX2010001577A
MX2010001577A MX2010001577A MX2010001577A MX2010001577A MX 2010001577 A MX2010001577 A MX 2010001577A MX 2010001577 A MX2010001577 A MX 2010001577A MX 2010001577 A MX2010001577 A MX 2010001577A MX 2010001577 A MX2010001577 A MX 2010001577A
Authority
MX
Mexico
Prior art keywords
egfr inhibitor
inhibitor treatment
predictive marker
predictive
marker
Prior art date
Application number
MX2010001577A
Other languages
English (en)
Inventor
Verena Lutz
Paul Delmar
Barbara Klughammer
Patricia Mcloughlin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010001577A publication Critical patent/MX2010001577A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un biomarcador el cual es predictivo para el beneficio clínico del tratamiento con inhibidor de EGFR en pacientes con cáncer.
MX2010001577A 2007-08-14 2008-08-07 Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. MX2010001577A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114300 2007-08-14
PCT/EP2008/006522 WO2009021683A2 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment

Publications (1)

Publication Number Publication Date
MX2010001577A true MX2010001577A (es) 2010-06-02

Family

ID=40227519

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001577A MX2010001577A (es) 2007-08-14 2008-08-07 Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Country Status (10)

Country Link
US (1) US20110245279A1 (es)
EP (1) EP2179058A2 (es)
JP (1) JP2010535523A (es)
KR (1) KR20100044851A (es)
CN (1) CN101946007A (es)
AU (1) AU2008286336A1 (es)
BR (1) BRPI0814354A2 (es)
CA (1) CA2695247A1 (es)
MX (1) MX2010001577A (es)
WO (1) WO2009021683A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11459618B2 (en) 2017-03-29 2022-10-04 Crown Bioscience, Inc. (Taicang) System and method for determining Cetuximab sensitivity on gastric cancer
US20220026415A1 (en) * 2018-11-26 2022-01-27 National Cancer Center A method for screening a therapeutic agent for cancer using binding inhibitor of cyclin-dependent kinase 1 (cdk1)-cyclin b1 and retinoic acid receptor responder 1 (rarres1) gene knockout animal model

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
KR101126560B1 (ko) * 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
US20060019284A1 (en) * 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells

Also Published As

Publication number Publication date
BRPI0814354A2 (pt) 2015-01-20
AU2008286336A1 (en) 2009-02-19
US20110245279A1 (en) 2011-10-06
EP2179058A2 (en) 2010-04-28
WO2009021683A2 (en) 2009-02-19
CA2695247A1 (en) 2009-02-19
WO2009021683A8 (en) 2010-06-17
CN101946007A (zh) 2011-01-12
KR20100044851A (ko) 2010-04-30
WO2009021683A3 (en) 2009-04-09
JP2010535523A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2010146059A3 (en) Biomarkers for igf-1r inhibitor therapy
HK1108284A1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
IN2012DN03012A (es)
EA201171367A1 (ru) Винилиндазолильные соединения
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
MX2013003594A (es) Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis de osteoblasticas en los huesosl.
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
HK1145342A1 (en) Prognosis prediction for melanoma cancer
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
MX2010001571A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors
WO2010015538A3 (en) Predictive marker for egfr inhibitor treatment
MX343803B (es) Complejo de ipp como marcador para tratamiento de erlotinib.
MX2010001573A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001577A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001583A (es) Maracdor predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001570A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001578A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001572A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001582A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
TN2009000448A1 (en) Use of hdac inhibitors for the treatment of bone destruction
MX2010001579A (es) Maracador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001580A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal